97-LB: Bringing Simulation Technologies to People with T1D: A Pilot Study
Background: Researchers have extensively used metabolic simulators as a fast, inexpensive, and safe way of testing novel treatment strategies. This work aims to bring this technology to people with T1D to enable unique patient/data interactions. Methods: A 5-week pilot study was carried out in 15 ad...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 70; no. Supplement_1 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
American Diabetes Association
01.06.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 0012-1797 1939-327X |
DOI | 10.2337/db21-97-LB |
Cover
Abstract | Background: Researchers have extensively used metabolic simulators as a fast, inexpensive, and safe way of testing novel treatment strategies. This work aims to bring this technology to people with T1D to enable unique patient/data interactions.
Methods: A 5-week pilot study was carried out in 15 adults with T1D using Control-IQ technology (age 36±13 years, HbA1c 6.5±0.7%) to evaluate acceptance of the proposed Web-Based Simulation Tool (WST). The study consisted of 1 week of observation (Phase 1) and 4 weeks of interaction with WST (Phase 2). Data were automatically collected via Tandem Diabetes Care t:connect web application, and used to generate personalized models of the participants’ glucose metabolism.
Results: Success rate in generating models was 86.4%, achieving an average MARD of 7.4±3.2%. Interaction time was 15.8±10.7 min per week. Comparing Phases 1 and 2, no variation was detected in time in range 70-180 mg/dl (80.1 [70.4,89.6]% vs. 80 [69.7,87.9]%). Time in 70-250 mg/dl increased slightly (94.2 [90.3,95.7]% vs. 96.2 [92.1,97.9]%), especially overnight (92.8 [88.3,98.2]% vs. 97.2 [91.8,99.6]%), and for participants who modified their pump settings based on WST simulations (90 [88.7,92.4]% vs. 94.5 [87.1,99.6]%). One subject tested COVID positive during the study and was excluded from this analysis due to abnormal hyperglycemia.
Analysis of Diabetes Distress Scale (DDS)-17 pre and post-system use shows a reduction in diabetes-related distress (2.2 [1.7,3.4] vs. 2 [1.7,2.4]). Trust, ease of use, and usefulness scores were 80 [60,80]%, 60 [60,80]%, and 80 [60,80]%, respectively. During the follow up interviews, 10 participants reported they enjoyed using WST and would implement it into their diabetes management; 2 did not like the system but see the potential of it for other people; 3 participants did not like the system at all.
Conclusions: Evidence from this study suggests that simulation technologies may empower people with T1D, making them more confident in their diabetes self-management. |
---|---|
AbstractList | Background: Researchers have extensively used metabolic simulators as a fast, inexpensive, and safe way of testing novel treatment strategies. This work aims to bring this technology to people with T1D to enable unique patient/data interactions. Methods: A 5-week pilot study was carried out in 15 adults with T1D using Control-IQ technology (age 36±13 years, HbA1c 6.5±0.7%) to evaluate acceptance of the proposed Web-Based Simulation Tool (WST). The study consisted of 1 week of observation (Phase 1) and 4 weeks of interaction with WST (Phase 2). Data were automatically collected via Tandem Diabetes Care t:connect web application, and used to generate personalized models of the participants' glucose metabolism. Results: Success rate in generating models was 86.4%, achieving an average MARD of 7.4±3.2%. Interaction time was 15.8±10.7 min per week. Comparing Phases 1 and 2, no variation was detected in time in range 70-180 mg/dl (80.1 [70.4,89.6]% vs. 80 [69.7,87.9]%). Time in 70-250 mg/dl increased slightly (94.2 [90.3,95.7]% vs. 96.2 [92.1,97.9]%), especially overnight (92.8 [88.3,98.2]% vs. 97.2 [91.8,99.6]%), and for participants who modified their pump settings based on WST simulations (90 [88.7,92.4]% vs. 94.5 [87.1,99.6]%). One subject tested COVID positive during the study and was excluded from this analysis due to abnormal hyperglycemia. Analysis of Diabetes Distress Scale (DDS)-17 pre and post-system use shows a reduction in diabetes-related distress (2.2 [1.7,3.4] vs. 2 [1.7,2.4]). Trust, ease of use, and usefulness scores were 80 [60,80]%, 60 [60,80]%, and 80 [60,80]%, respectively. During the follow up interviews, 10 participants reported they enjoyed using WST and would implement it into their diabetes management; 2 did not like the system but see the potential of it for other people; 3 participants did not like the system at all. Conclusions: Evidence from this study suggests that simulation technologies may empower people with T1D, making them more confident in their diabetes self-management. Background: Researchers have extensively used metabolic simulators as a fast, inexpensive, and safe way of testing novel treatment strategies. This work aims to bring this technology to people with T1D to enable unique patient/data interactions. Methods: A 5-week pilot study was carried out in 15 adults with T1D using Control-IQ technology (age 36±13 years, HbA1c 6.5±0.7%) to evaluate acceptance of the proposed Web-Based Simulation Tool (WST). The study consisted of 1 week of observation (Phase 1) and 4 weeks of interaction with WST (Phase 2). Data were automatically collected via Tandem Diabetes Care t:connect web application, and used to generate personalized models of the participants’ glucose metabolism. Results: Success rate in generating models was 86.4%, achieving an average MARD of 7.4±3.2%. Interaction time was 15.8±10.7 min per week. Comparing Phases 1 and 2, no variation was detected in time in range 70-180 mg/dl (80.1 [70.4,89.6]% vs. 80 [69.7,87.9]%). Time in 70-250 mg/dl increased slightly (94.2 [90.3,95.7]% vs. 96.2 [92.1,97.9]%), especially overnight (92.8 [88.3,98.2]% vs. 97.2 [91.8,99.6]%), and for participants who modified their pump settings based on WST simulations (90 [88.7,92.4]% vs. 94.5 [87.1,99.6]%). One subject tested COVID positive during the study and was excluded from this analysis due to abnormal hyperglycemia. Analysis of Diabetes Distress Scale (DDS)-17 pre and post-system use shows a reduction in diabetes-related distress (2.2 [1.7,3.4] vs. 2 [1.7,2.4]). Trust, ease of use, and usefulness scores were 80 [60,80]%, 60 [60,80]%, and 80 [60,80]%, respectively. During the follow up interviews, 10 participants reported they enjoyed using WST and would implement it into their diabetes management; 2 did not like the system but see the potential of it for other people; 3 participants did not like the system at all. Conclusions: Evidence from this study suggests that simulation technologies may empower people with T1D, making them more confident in their diabetes self-management. |
Author | BRETON, MARC D. WAKEMAN, CHRISTIAN A. NASS, RALF COLMEGNA, PATRICIO OLIVERI, MARY C. MCFADDEN, RYAN BISIO, ALESSANDRO |
Author_xml | – sequence: 1 givenname: PATRICIO surname: COLMEGNA fullname: COLMEGNA, PATRICIO organization: Charlottesville, VA – sequence: 2 givenname: ALESSANDRO surname: BISIO fullname: BISIO, ALESSANDRO organization: Charlottesville, VA – sequence: 3 givenname: RYAN surname: MCFADDEN fullname: MCFADDEN, RYAN organization: Charlottesville, VA – sequence: 4 givenname: CHRISTIAN A. surname: WAKEMAN fullname: WAKEMAN, CHRISTIAN A. organization: Charlottesville, VA – sequence: 5 givenname: MARY C. surname: OLIVERI fullname: OLIVERI, MARY C. organization: Charlottesville, VA – sequence: 6 givenname: RALF surname: NASS fullname: NASS, RALF organization: Charlottesville, VA – sequence: 7 givenname: MARC D. surname: BRETON fullname: BRETON, MARC D. organization: Charlottesville, VA |
BookMark | eNotkMtqwzAUREVJoUnaTb9A0F1BrV7WtbNL0lfA0EC86E74IScKjpVKNiV_X6cpMzCbw1zuTNCoda1B6J7RJy4EPFcFZyQBki6u0JglIiGCw9cIjSllnDBI4AZNQthTStWgMVr9wTO88LbdDsYbe-ibvLOuxZkpd61r3NaagDuH18YdG4N_bLfDGXuZ4Tle28Z1eNP11ekWXdd5E8zdf05R9vaaLT9I-vm-Ws5TUiohiKliAChiGVXC5KwAWZiCilJGlCvJTQwsUrWByjBZSJmzuK6FqmoaSwDJSjFFD5fao3ffvQmd3rvet8NFzSPFuVLD2wP1eKFK70LwptZHbw-5P2lG9XkpfV5KJ6DThfgFFIhazg |
ContentType | Journal Article |
Copyright | Copyright American Diabetes Association Jun 1, 2021 |
Copyright_xml | – notice: Copyright American Diabetes Association Jun 1, 2021 |
DBID | AAYXX CITATION K9. NAPCQ |
DOI | 10.2337/db21-97-LB |
DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X |
ExternalDocumentID | 10_2337_db21_97_LB |
Genre | Conference Proceeding |
GroupedDBID | --- .55 .XZ 08P 0R~ 18M 29F 2WC 354 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAFWJ AAQQT AAWTL AAYEP AAYXX ABOCM ACGFO ACGOD ACPRK ADBBV AEGXH AENEX AERZD AHMBA AIAGR AIZAD ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BES BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EMOBN EX3 F5P FRP GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO K2M KQ8 L7B M5~ O5R O5S O9- OHH OK1 OVD P2P PCD Q2X RHI RPM SJN SV3 TDI TEORI TR2 VVN W8F WH7 WOQ WOW X7M YFH YHG YOC ZY1 ~KM K9. NAPCQ |
ID | FETCH-LOGICAL-c633-ed8777b845d3ea1b74beb03c4502642e87156fe7de14b44a18ff36df0847741c3 |
ISSN | 0012-1797 |
IngestDate | Mon Jun 30 10:52:48 EDT 2025 Tue Jul 01 02:40:56 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c633-ed8777b845d3ea1b74beb03c4502642e87156fe7de14b44a18ff36df0847741c3 |
Notes | ObjectType-Conference Proceeding-1 SourceType-Scholarly Journals-1 content type line 14 |
PQID | 2562266193 |
PQPubID | 34443 |
ParticipantIDs | proquest_journals_2562266193 crossref_primary_10_2337_db21_97_LB |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-06-01 20210601 |
PublicationDateYYYYMMDD | 2021-06-01 |
PublicationDate_xml | – month: 06 year: 2021 text: 2021-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationYear | 2021 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
SSID | ssj0006060 |
Score | 2.359453 |
Snippet | Background: Researchers have extensively used metabolic simulators as a fast, inexpensive, and safe way of testing novel treatment strategies. This work aims... |
SourceID | proquest crossref |
SourceType | Aggregation Database Index Database |
SubjectTerms | Diabetes Diabetes mellitus Glucose metabolism Hyperglycemia Simulation |
Title | 97-LB: Bringing Simulation Technologies to People with T1D: A Pilot Study |
URI | https://www.proquest.com/docview/2562266193 |
Volume | 70 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLfKkBAXxKcYDGQJbiijsZ2v3dyko2FNN5UgyimaY0eqtLUTZBz463m289Wxw-ASRa7sqO_9_L78_B5C78cSzAyvihzPr4jDhA9bikjY7qwsWVgp1620o5gt_NlX9nnlrUajX4OspetaHJa_b71X8j9chTHgq74l-w-c7RaFAXgH_sITOAzPO_E4Cpz5RPv0Ex2dM7W115dNP64-aL62VRzOTK64DbzmbmKvpJ-tL7a1SSbcOd5NBhHZm716BrGD-HSeTT8tuI3m5cs0Tk87_z4FMW0kzxx4zBfJsvspi495kkxNgsHyO-8Og77xk2nGzXA8W6Zf8pQvPvDDYWCCDBKoWmHrEl391OpTZeVrRCOHkmA1FMC2c0gDNNPM1ERGC_c2EU-oKRIghU4t0VTuFVl7eH9Dv3VZh-Dv6NmFnltEQTGf3EP3SRDY4_30pNPg4NTZq0vNH7BlbfXcj_13dw2ZXT1ujJP8MXrUeBWYW4g8QSO1eYoeZE3exDOUmrWOcIsT3OMED3GC6y22OMEaJxhwcoQ5NijBBiXPUX48zeOZ0zTRcEqfUkdJXfBRhMyTVJ27ImBCiTEtmQfONyMK_GXYpSqQymWCsXM3rCrqy2oMVgsYmyV9gfY22416iXDANGHA0pFjwQQhgsgwCqKx9GUQCr_cR-9aghRXtlRK8TfJ99FBS6ui2Uo_C7C7ibYUI_rqTou8Rg97xB2gvfrHtXoDxmEt3hpO_gG5h1kw |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=97-LB%3A+Bringing+Simulation+Technologies+to+People+with+T1D%3A+A+Pilot+Study&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=COLMEGNA%2C+PATRICIO&rft.au=BISIO%2C+ALESSANDRO&rft.au=MCFADDEN%2C+RYAN&rft.au=WAKEMAN%2C+CHRISTIAN+A.&rft.date=2021-06-01&rft.issn=0012-1797&rft.eissn=1939-327X&rft.volume=70&rft.issue=Supplement_1&rft_id=info:doi/10.2337%2Fdb21-97-LB&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db21_97_LB |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |